Trial Profile
NOBORI 2: a prospective, multi-centre, observational study of the Nobori [biolimus-A9] drug eluting stent system.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Feb 2017
Price :
$35
*
At a glance
- Drugs Umirolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms NOBORI 2
- Sponsors Terumo
- 04 Sep 2013 Results from seven major Italian cath labs presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.
- 10 Apr 2009 Status is active, no longer recruiting according to a Terumo media release.
- 28 Jun 2008 New trial record.